文献速递中毒与环境急症消化、代谢与肾脏急症

识别急诊科启动丁丙诺啡治疗的障碍:密歇根州治疗机构可及性的空间分析

Identifying barriers to emergency department-initiated buprenorphine: A spatial analysis of treatment facility access in Michigan.
PubMed 文献 · Am J Emerg Med · 2021-11-11
一句话结论密歇根州仅一半急诊科在10英里内有丁丙诺啡治疗机构,扩大急诊启动丁丙诺啡可能需替代照护模式。

该研究比较密歇根州急诊科与提供丁丙诺啡治疗的门诊机构的地理分布,并识别与治疗可及性相关的急诊和地理因素。治疗机构数据来自SAMHSA 2018年全国药物与酒精滥用治疗机构目录,急诊科数据来自密歇根急诊医师学会2018年急诊科目录,使用5、10、20英里网络缓冲区进行地理空间分析。在131家非完全儿科急诊科中,57家(43.5%)在5英里内有丁丙诺啡治疗机构,66家(50.4%)在10英里内有机构。10英里内有接受医疗补助的门诊丁丙诺啡治疗机构的急诊科,其平均床位数为41张 vs 15张(p<0.0001),年患者量为58,616 vs 17,484(p<0.0001)。有至少一家丁丙诺啡治疗机构的县平均人口为286,957 vs 44,757(p=0.005),阿片类药物过量死亡年率为每10万人18.3 vs 13.0(p=0.02),但阿片相关住院和社会经济困扰相似。作者认为,在类似密歇根州的州,扩大急诊启动丁丙诺啡的可及性可能需要开发替代照护模式。

要点

  • 在密歇根州131家非完全儿科急诊科中,仅57家(43.5%)在5英里内有丁丙诺啡治疗机构,66家(50.4%)在10英里内有机构。
  • 10英里内有接受医疗补助的门诊丁丙诺啡治疗机构的急诊科,平均床位数为41张 vs 15张(p<0.0001),年患者量为58,616 vs 17,484(p<0.0001)。
  • 有至少一家丁丙诺啡治疗机构的县平均人口为286,957 vs 44,757(p=0.005),阿片类药物过量死亡年率为每10万人18.3 vs 13.0(p=0.02)。
  • 有与无丁丙诺啡治疗机构的县在阿片相关住院和社会经济困扰方面相似。
  • 作者认为,在类似密歇根州的州,扩大急诊启动丁丙诺啡的可及性可能需要开发替代照护模式。

适用人群与场景

  • 密歇根州131家非完全儿科急诊科,数据来自密歇根急诊医师学会2018年急诊科目录。
  • 密歇根州有急诊科的县,比较有与无至少一家丁丙诺啡治疗机构的县。

研究设计与关键结果

  • 研究类型为地理空间分析,比较密歇根州急诊科与提供丁丙诺啡治疗的门诊机构的地理分布。
  • 治疗机构数据来自SAMHSA 2018年全国药物与酒精滥用治疗机构目录,使用5、10、20英里网络缓冲区。
  • 在131家非完全儿科急诊科中,57家(43.5%)在5英里内有丁丙诺啡治疗机构,66家(50.4%)在10英里内有机构。
  • 10英里内有接受医疗补助的门诊丁丙诺啡治疗机构的急诊科,平均床位数为41张 vs 15张(p<0.0001),年患者量为58,616 vs 17,484(p<0.0001)。
  • 有至少一家丁丙诺啡治疗机构的县平均人口为286,957 vs 44,757(p=0.005),阿片类药物过量死亡年率为每10万人18.3 vs 13.0(p=0.02)。
  • 有与无丁丙诺啡治疗机构的县在阿片相关住院和社会经济困扰方面相似。

证据类型、等级与局限

  • 证据类型:地理空间分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,鉴于仅一半密歇根州急诊科在10英里内有丁丙诺啡治疗机构,在类似密歇根州的州,扩大急诊启动丁丙诺啡的可及性可能需要开发替代照护模式。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVES: Emergency department (ED)-initiated buprenorphine/naloxone has been shown to improve treatment retention and reduce illicit opioid use; however, its potential may be limited by a lack of accessible community-based facilities. This study compared one state's geographic distribution of EDs to outpatient treatment facilities that provide buprenorphine treatment and identified ED and geographic factors associated with treatment access.

METHODS: Treatment facility data were obtained from the SAMHSA 2018 National Directory of Drug and Alcohol Abuse Treatment Facilities, and ED data were obtained from the Michigan College of Emergency Physician's 2018 ED directory. Geospatial analysis compared EDs to buprenorphine treatment facilities using 5-, 10-, and 20-mile network buffers.

RESULTS: Among 131 non-exclusively pediatric EDs in Michigan, 57 (43.5%) had a buprenorphine treatment facility within 5 miles, and 66 (50.4%) had a facility within 10 miles. EDs within 10 miles of a Medicaid-accepting, outpatient buprenorphine treatment facility had higher average numbers of beds (41 vs. 15; p < 0.0001) and annual patient volumes (58,616 vs. 17,484; p < 0.0001) compared to those without. Among Michigan counties with EDs, those with at least one buprenorphine facility had larger average populations (286,957 vs. 44,757; p = 0.005) and higher annual rates of opioid overdose deaths (mean 18.3 vs. 13.0 per 100,000; p = 0.02) but were similar in terms of opioid-related hospitalizations and socioeconomic distress.

CONCLUSION: Only half of Michigan EDs are within 10 miles of a buprenorphine treatment facility. Given these limitations, expanding access to ED-initiated buprenorphine in states similar to Michigan may require developing alternative models of care.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Dora-Laskey A, King A, Sadler R, et al. Identifying barriers to emergency department-initiated buprenorphine: A spatial analysis of treatment facility access in Michigan. Am J Emerg Med. 2021. PMID: 34826787. doi:10.1016/j.ajem.2021.11.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。